BCL2 and B-cell chronic lymphocytic leukemia: Lisaftoclax (APG-2575, Ascentage Pharma, Suzhou, China, and Rockville, MD, USA) is a novel, specific BCL-2 inhibitor active in patients with TN and RR CLL/SLL, including those with 17p deletion and progressive disease after BTKi therapy [98].